AR124130A1 - Variantes de anticuerpos bovinos - Google Patents

Variantes de anticuerpos bovinos

Info

Publication number
AR124130A1
AR124130A1 ARP210103234A ARP210103234A AR124130A1 AR 124130 A1 AR124130 A1 AR 124130A1 AR P210103234 A ARP210103234 A AR P210103234A AR P210103234 A ARP210103234 A AR P210103234A AR 124130 A1 AR124130 A1 AR 124130A1
Authority
AR
Argentina
Prior art keywords
igg
bovine
modified
modified igg
variants
Prior art date
Application number
ARP210103234A
Other languages
English (en)
Spanish (es)
Inventor
Catherine J Strietzel
Sandra Ann Marie Lightle
Henry Luis Campos
Yaqi Zhu
Gregory John Fici
Alexander Pogacsas Ruhland Bally
Prajna Shanbhogue
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of AR124130A1 publication Critical patent/AR124130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP210103234A 2020-11-20 2021-11-23 Variantes de anticuerpos bovinos AR124130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063116491P 2020-11-20 2020-11-20

Publications (1)

Publication Number Publication Date
AR124130A1 true AR124130A1 (es) 2023-02-15

Family

ID=79018979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103234A AR124130A1 (es) 2020-11-20 2021-11-23 Variantes de anticuerpos bovinos

Country Status (12)

Country Link
US (1) US20230416410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247851A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551194A (cg-RX-API-DMAC7.html)
KR (1) KR20230110297A (cg-RX-API-DMAC7.html)
CN (1) CN116615463A (cg-RX-API-DMAC7.html)
AR (1) AR124130A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021382704A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023008490A2 (cg-RX-API-DMAC7.html)
CA (1) CA3202089A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007146A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023005896A (cg-RX-API-DMAC7.html)
WO (1) WO2022109313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255933A4 (en) 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
AU2023320519A1 (en) * 2022-08-05 2025-01-30 Zoetis Services Llc Bovine antibody mutants
AU2023334358A1 (en) * 2022-09-02 2025-03-13 Zoetis Services Llc Porcine antibody mutants
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
RS58801B1 (sr) * 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease

Also Published As

Publication number Publication date
JP2023551194A (ja) 2023-12-07
EP4247851A1 (en) 2023-09-27
WO2022109313A1 (en) 2022-05-27
CN116615463A (zh) 2023-08-18
CA3202089A1 (en) 2022-05-27
AU2021382704A9 (en) 2025-03-27
CO2023007146A2 (es) 2023-06-30
MX2023005896A (es) 2023-07-03
US20230416410A1 (en) 2023-12-28
AU2021382704A1 (en) 2023-06-08
KR20230110297A (ko) 2023-07-21
BR112023008490A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
ECSP22015044A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BR112021021843A8 (pt) Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
EA201790342A1 (ru) Антитела к trem2 и способы их применения
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CR20110161A (es) Anticuerpos contra la il17 humana y usos de los mismos
NZ758301A (en) Anti-trem2 antibodies and methods of use thereof
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
JOP20220204A1 (ar) الأجسام المضادة لـ cd19 البشرية
PE20190261A1 (es) Anticuerpos que reconocen tau
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190235A1 (ru) Антитела к cd33 и способы их применения
PE20170782A1 (es) Anticuerpos frente a cd73 y usos de los mismos
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PE20200695A1 (es) Anticuerpos que reconocen tau
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2023005896A (es) Variantes de anticuerpos bovinos.
MX2025009846A (es) Composiciones que comprenden moleculas de acido nucleico que codifican anticuerpos sinteticos anti-il-6 y anti-cd126
BR112022011122A2 (pt) Epítopos e anticorpos de trpv1